Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GX-I7 + temozolomide
- Development stage
- Discontinued
- Lead developer
- Genexine
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intramuscular (GX-I7), Oral (temozolomide)
01
Overview
GX-I7 + temozolomide is an investigational combination therapy for glioblastoma that includes **GX-I7 (also known as NT-I7, efineptakin alfa, rhIL-7-hyFc)**, a long-acting recombinant human interleukin-7 (IL-7) fusion protein, and **temozolomide**, a well-established oral alkylating agent used as chemotherapy. GX-I7 acts by stimulating T-cell proliferation and restoring lymphocyte counts, which may counteract chemotherapy-induced lymphopenia, while temozolomide induces DNA damage and cell death in tumor cells. The combination aims to enhance anti-tumor immune responses and improve outcomes for patients with newly diagnosed glioblastoma who have completed standard chemoradiation. GX-I7 is in development by Genexine and NeoImmuneTech; temozolomide is a widely used generic chemotherapy agent[1][2][4][5][7].
- Other names
- NT-I7 + temozolomide
02
Targets
O6-MeG (O6-methylguanine DNA lesion)IL7R (Interleukin-7 Receptor)
Beyond the preview
Go deeper on GX-I7 + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GX-I7 + temozolomide.